Kazia Therapeutics Ltd ADR KZIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
-
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
-
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
-
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
-
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
-
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
-
Kazia Therapeutics Limited Announces Proposed Public Offering
-
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Trading Information
- Previous Close Price
- $9.29
- Day Range
- $8.96–9.10
- 52-Week Range
- $4.97–17.37
- Bid/Ask
- $8.97 / $9.18
- Shares Outstanding
- 15.55M
- Market Cap
- $139.94M
- Volume/Avg
- 61,265 / 262,972
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 765.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Valuation
|
Metric
|
KZIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.39 |
Price/Sales | 765.83 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KZIA
|
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 2.87 |
Interest Coverage | — |
Quick Ratio
KZIA
Profitability
|
Metric
|
KZIA
|
|---|---|
Return on Assets (Normalized) | −38.68% |
Return on Equity (Normalized) | −107.05% |
Return on Invested Capital (Normalized) | −106.74% |
Return on Assets
KZIA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yTH>z@B | LOCK|<rV^ | $128B | |||
| Moderna Inc
MRNA
| LOCK|<cJhyJ@ | LOCK|?p | $78B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#J$SG?C | LOCK|#qmjW | $76B | |||
| argenx SE ADR
ARGX
| LOCK|?!sq#! | LOCK|Yc | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FvjPGy% | LOCK|@>h | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!Ycrlz< | LOCK|HlnVG | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s<!n^y&s | LOCK|!d<H | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|y?MD@Yw | LOCK|&p | $24B | |||
| Incyte Corp
INCY
| LOCK|vmG@$r | LOCK|!@m | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&WQQk#Y | LOCK|LMr | $15B |
United States